MSB Trading - 2019, page-2791

If one compares this 40% success probability in Cantor’s analysis to the information provided by @otherperspective regarding for example the likelihood of success of trials further to a “futility” study, one understands the huge upside of Revascor. I noticed also that Remestemcel L is estimated at 85% and one poster here (sorry forgot who) wrote that even SI ascribed a 90% chance of BLA approval, while we know how successful phase 3 trial, EAP were and that the market is growing exponentially in Japan. Nothing is as sure as death and taxes says the adage, certitudes flaws judgment.